ANASCORP-US.COM: Keyword Density Checker

Total words: 1788 | 2-word phrases: 461 | 3-word phrases: 515 | 4-word phrases: 536

PAGE INFO

Title	Try to keep the title under 60 characters (77 characters) ANASCORP® [centruroides (scorpion) immune F(ab')? (equine) injection] \|
Description	Try to keep the meta description between 50 - 160 characters (0 characters)
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (10 characters) ANASCORP®

#	Keyword	Frequency	Density
1	of scorpion envenomation	5	0.97%
2	scorpion immune fab?	4	0.78%
3	at risk for	4	0.78%
4	patients in the	4	0.78%
5	risk for a	4	0.78%
6	in the clinical	4	0.78%
7	signs of scorpion	4	0.78%
8	during the infusion	4	0.78%
9	adverse reactions contact	3	0.58%
10	patients with clinical	3	0.58%
11	clinical signs of	3	0.58%
12	delayed allergic reactions	3	0.58%
13	scorpion envenomation important	3	0.58%
14	disease therapeutics inc	3	0.58%
15	rare disease therapeutics	3	0.58%
16	severe hypersensitivity reaction	3	0.58%
17	centruroides scorpion immune	3	0.58%
18	equinederived antivenom indicated	3	0.58%
19	scorpion immune fab2	3	0.58%
20	anascorp® centruroides scorpion	3	0.58%
21	report suspected adverse	3	0.58%
22	suspected adverse reactions	3	0.58%
23	injection is an	3	0.58%
24	indicated for treatment	3	0.58%
25	antivenom indicated for	3	0.58%
26	reaction delayed allergic	2	0.39%
27	hypersensitivity reaction delayed	2	0.39%
28	for a severe	2	0.39%
29	reactions or serum	2	0.39%
30	protein and be	2	0.39%

#	Keyword	Frequency	Density
1	signs of scorpion envenomation	4	0.75%
2	patients in the clinical	4	0.75%
3	at risk for a	4	0.75%
4	clinical signs of scorpion	3	0.56%
5	anascorp® centruroides scorpion immune	3	0.56%
6	of scorpion envenomation important	3	0.56%
7	rare disease therapeutics inc	3	0.56%
8	suspected adverse reactions contact	3	0.56%
9	antivenom indicated for treatment	3	0.56%
10	equinederived antivenom indicated for	3	0.56%
11	centruroides scorpion immune fab?	3	0.56%
12	centruroides scorpion immune fab2	3	0.56%
13	patients with followup visits	2	0.37%
14	reactions or serum sickness	2	0.37%
15	antivenomantitoxin may have become	2	0.37%
16	sensitized to equine protein	2	0.37%
17	to equine protein and	2	0.37%
18	equine protein and be	2	0.37%
19	or serum sickness eg	2	0.37%
20	allergic reactions or serum	2	0.37%
21	risk for a severe	2	0.37%
22	with followup visits for	2	0.37%
23	delayed allergic reactions or	2	0.37%
24	hypersensitivity reaction delayed allergic	2	0.37%
25	signs and symptoms of	2	0.37%
26	and treat appropriately if	2	0.37%
27	monitor patients with followup	2	0.37%
28	arthralgia and treat appropriately	2	0.37%
29	and diphenhydramine hydrochloride is	2	0.37%
30	treat appropriately if necessary	2	0.37%
31	plasma it may therefore	2	0.37%
32	amounts of cresol from	2	0.37%
33	trace amounts of cresol	2	0.37%
34	viruses reaction to cresol	2	0.37%
35	eg viruses reaction to	2	0.37%
36	agents eg viruses reaction	2	0.37%
37	risk of transmitting infectious	2	0.37%
38	may therefore carry a	2	0.37%
39	it may therefore carry	2	0.37%
40	horse plasma it may	2	0.37%

#	URL	Whois	Check
1	https://www.fda.gov/medwatch	Whois	fda.gov
2	https://www.fda.gov/medwatch	Whois	fda.gov
3	https://www.fda.gov/medwatch	Whois	fda.gov
4	https://anovorx.com/prescribers/	Whois	anovorx.com